Investors

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
« Back
BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference

NEW YORK and PETACH TIKVAH, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwright & Co. 20th Annual Investor Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel.

Presentation Details:    
Date: 
Time: 
Speaker:
Webcast:
  Thursday, September 6
5:00 PM Eastern Time
Ralph Kern, MD., MHSc., Chief Operating and Chief Medical Officer
https://goo.gl/uWRdkU

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 100 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the US, a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the Company's website at www.brainstorm-cell.com.

CONTACTS
Media:
Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

 

Primary Logo

BrainStorm Cell Therapeutics Inc.